Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...
Oct 20, 2025, 7:03 AM EDT - 5 days ago
Oct 20, 2025, 7:01 AM EDT - 5 days ago
Oct 8, 2025, 9:56 AM EDT - 16 days ago
Oct 3, 2025, 10:51 AM EDT - 21 days ago
Oct 3, 2025, 7:34 AM EDT - 22 days ago
Sep 13, 2025, 11:50 AM EDT - 5 weeks ago
Sep 9, 2025, 7:09 AM EDT - 6 weeks ago
Aug 28, 2025, 5:40 PM EDT - 2 months ago
Aug 22, 2025, 10:15 AM EDT - 2 months ago
Aug 18, 2025, 9:45 AM EDT - 2 months ago
Aug 18, 2025, 8:45 AM EDT - 2 months ago
Aug 18, 2025, 8:03 AM EDT - 2 months ago
Aug 13, 2025, 4:10 PM EDT - 2 months ago
Aug 13, 2025, 8:03 AM EDT - 2 months ago
Aug 4, 2025, 2:46 PM EDT - 2 months ago
Jul 22, 2025, 6:25 PM EDT - 3 months ago
Jun 30, 2025, 8:03 AM EDT - 4 months ago
Jun 26, 2025, 7:33 AM EDT - 4 months ago
Jun 3, 2025, 6:03 AM EDT - 5 months ago
May 29, 2025, 8:03 AM EDT - 5 months ago
May 14, 2025, 4:10 PM EDT - 5 months ago
Apr 28, 2025, 8:03 AM EDT - 6 months ago
Apr 22, 2025, 8:03 AM EDT - 6 months ago
Mar 20, 2025, 4:10 PM EDT - 7 months ago
Mar 1, 2025, 11:00 AM EST - 8 months ago
Feb 19, 2025, 8:03 AM EST - 8 months ago
Feb 12, 2025, 8:03 AM EST - 9 months ago
Feb 2, 2025, 11:00 AM EST - 9 months ago
Jan 27, 2025, 11:15 AM EST - 9 months ago